The rising price of insulin has become ... Biosimilar insulin is also on its way, which could further erode potential sales. By comparison, a new product in Lilly’s diabetes portfolio, Mounjaro ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus ... charging PBMs with driving up prices for specialty drugs to treat ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

Sanofi has launched its new insulin ... version of Lantus has been launched in a handful of Eastern European markets at a discount of 15-20 per cent to Sanofi's brand price. Biosimilars are ...

and insulin manufacturers are conspiring to artificially inflate insulin prices for profit. Rising Insulin Costs Impact OKC Emergency Services Oklahoma City uses insulin during emergency calls to ...

Columbus joined a slough of cities, states and counties in suing drug companies and pharmacy benefit managers who they say artificially raised insulin prices for decades and profited from it ...

As of Jan. 23, 2025, Trump has not gotten rid of Medicare’s $35 cap on insulin prices, nor has he changed the $35 cap on out-of-pocket costs for some insulin products sold to Americans not on ...

Columbus City Attorney Zach Klein announced that the city has filed a lawsuit against several drug companies and pharmacy benefit managers (PBMs) for allegedly inflating insulin prices for decades ...

The suit says insulin vials cost as little as $2 to produce, were priced at $20 per vial in the 1990s, and “now range in price from $300 to over $700.” The city accuses a number of defendants ...